Salvia divinorum is a small perennial shrub that has gained recent popularity among the drug-using subculture as a legal alternative to hallucinogens. Salvinorin A, the main active compound found in the S.divinorum plant, is an atypical hallucinogen with pharmacological selectivity at kappa opioid (KOP) receptor sites and is a unique non-nitrogenous neoclerodane diterpene which is structurally distinct from other opioid compounds. The novel structure of salvinorin A and its specific binding affinity to KOP receptors provide a unique opportunity to investigate neurochemical mechanisms of hallucination and hallucinogenic compounds. The current investigation assessed the substitution of salvinorin A in 16 male Sprague-Dawley rats trained to discriminate either the prototypical serotonergic hallucinogen, LSD (0.08mg/kg, S.C., n=8) or the dissociative anesthetic and glutamatergic hallucinogen, ketamine (8.0mg/kg, I.P., n=8) from vehicle under a FR 20 schedule of food-reinforced responding. Results indicated that neither LSD nor ketamine discrimination generalized to salvinorin A. These findings are consistent with the growing body of evidence that salvinorin A is pharmacologically distinct from other traditional hallucinogenic compounds.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pbb.2010.05.014DOI Listing

Publication Analysis

Top Keywords

lsd ketamine
8
sprague-dawley rats
8
hallucinogenic compounds
8
salvinorin
6
salvinorin fails
4
fails substitute
4
substitute discriminative
4
discriminative stimulus
4
stimulus effects
4
effects lsd
4

Similar Publications

Purpose Of Review: Chronic pain affects approximately 1.5 billion people worldwide, representing the leading cause of disability and a significant financial burden on healthcare systems. Conventional treatments, such as opioids and non-steroidal anti-inflammatory drugs, are frequently linked to adverse effects, including dependency and gastrointestinal issues, and often offer limited long-term relief.

View Article and Find Full Text PDF

During the COVID-19 pandemic, the sampling method for the National HIV Behavioral Surveillance (NHBS) in San Francisco changed from physical venue time-location sampling (TLS) to online or virtual venue TLS for men who have sex with men (MSM). We present differences in the samples of MSM recruited using physical venue TLS in 2017 and virtual venue TLS in 2021. We further assess changes in preventive and risk behaviors from 2017 to 2021 after controlling for differences in the sample compositions with multivariable Poisson models using GLM with robust standard errors.

View Article and Find Full Text PDF

Quality of reporting on psychological interventions in psychedelic treatments: a systematic review.

Lancet Psychiatry

January 2025

Champalimaud Research and Clinical Centre, Champalimaud Foundation, Lisbon, Portugal; Faculdade de Ciências Médicas, NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal. Electronic address:

Although studies of psychedelic-assisted psychotherapy are accumulating, there is no consensus regarding best practice of the psychotherapeutic component. In this systematic review, we summarised the quality of reporting on psychological interventions in research about psychedelic treatments. The design followed PRISMA guidelines and was preregistered in PROSPERO (CRD42022319221).

View Article and Find Full Text PDF

Background: The interest in psychedelics as a therapeutic intervention for existential distress of people with terminal illness grounds on their mechanism of action and effect on the spiritual/existential aspects accompanying end-of-life experiences.

Aims: This systematic review and network meta-analysis aimed at examining the efficacy and safety of psychedelic compounds for existential distress in terminally ill people.

Methods: PubMed, CINAHL, PsycINFO, EMBASE, and clinicaltrials.

View Article and Find Full Text PDF
Article Synopsis
  • A meta-analysis was conducted to evaluate whether psychoplastogens like ketamine and psychedelics increase peripheral BDNF levels in humans, which have been suggested as biomarkers for neuroplasticity.
  • The analysis included data from 29 studies and found no significant evidence that these substances elevate peripheral BDNF levels, regardless of various factors such as drug type, dosage, or participant characteristics.
  • The findings imply that peripheral BDNF may not be a reliable marker for assessing neuroplasticity changes in humans after psychoplastogen administration, highlighting potential discrepancies between preclinical and human studies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!